Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
BACKGROUND
Unquestionably viral diversity and genetic heterogeneity in hepatitis C virus (HCV) infection and other viral diseases play an essential role in viral immune escape and the development of chronicity. Despite this knowledge most vaccine approaches against HCV have excluded this important issue. Moreover the feasibility of developing an effective HCV vaccine has been questioned, mainly because prophylactic immunity against HCV cannot be achieved in chimpanzees by either vaccination or previous HCV infection, and reinfection in men has been reported, most likely due to genetic shift and immune escape. To analyse and characterize a new technique of a 'multigenotype'- and/or 'library'-vaccine, we established an envelope 1 (E1) plasmid vaccine against HCV and characterized humoral and cellular immune responses after vaccination in a mouse model.


METHODS
Normally genetic information of one or two target proteins is cloned into a DNA-vaccine. In our approach we cloned a defined number of different genotypes and subtypes (defined vaccine, DV) or the genetic information from 20 patients (undefined) into a plasmid (library vaccine, LV).


RESULTS
As expected, immunized animals showed both stronger humoral (ELISA) and cellular (T-cell proliferation, ELISPOT) immune responses against genotype 1, since the stimulating antigen was genotype 1 derived. However, not all genotype 1 immunized animals recognized this viral antigen leading to the assumption that some epitopes lost their immunogenicity through a change in the amino acid sequence. Interestingly, some of the genotype 4 and 5 immunized mice sera were able to react against E1 protein.


CONCLUSIONS
Most of the assays showed immune reactivity against the DV or LV vaccine demonstrating the cross-reactive potential of such a vaccination approach. This cloning and immunization strategy based on the viral heterogeneity of the virus has in our view major implications for HCV, a virus with a broad viral genetic diversity, and may become in the future in the context of DNA- or viral-based vaccination strategies a possibility to overcome viral immune escape both in the prophylactic or therapeutic setting.
Encke
J
J
University of Heidelberg, Heidelberg, Germany. jens_encke@med.uni-heidelberg.de
Radunz
W
W
Eisenbach
C
C
Geib
J
J
Gehrke
S
S
Pfaff
E
E
Stremmel
W
W
D000818:Animals; D004195:Disease Models, Animal; D005838:Genotype; D006526:Hepatitis C / Q000276:immunology / Q000517:prevention & control*; D018937:Hepatitis C Antibodies / Q000096:biosynthesis / Q000276:immunology; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D014611:Vaccination; D019444:Vaccines, DNA / Q000235:genetics; D014761:Viral Hepatitis Vaccines / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use
D018937:Hepatitis C Antibodies; D019444:Vaccines, DNA; D014761:Viral Hepatitis Vaccines